A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma — Stella

Recruiting

Back to Metastatic Renal Cell Carcinoma trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

United States

Brigham and Women's Hospital, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

Key details

Phase

Safety & dosing

Sponsor

Stephanie Berg

Collaborators

Pfizer

Enrollment target

~25 participants

Started

November 2025

Primary completion

October 2026

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov